Alirocumab and Reverse Cholesterol Transport

Summary

Alirocumab is an injectable treatment for elevated blood cholesterol. The hypothesis of this study is that it also increases cholesterol excretion from the body into the stool, a process sometimes called reverse cholesterol transport. A cholesterol metabolic study will be done before and after 6 weeks of alirocumab treatment. If alirocumab increases reverse cholesterol transport, it is possible that this action provides additional protection from cardiovascular disease.

Timeline

Start

2017-06-01

Primary completion

2018-06-04

Completion

2018-07-30

Drugs

Indications